Gene and Cell Therapies for Blood Disorders
Gene and cell therapies are cutting-edge medical procedures that alter the patient's genetic makeup or cells in an effort to treat or improve blood diseases.
Gene therapy includes adding new genes or altering existing genes to treat genetic mutations that result in blood problems. To do this, the new genetic material might be introduced into the patient's cells via viruses or other vectors. Inherited blood diseases including sickle cell disease and beta-thalassemia have showed potential for treatment with gene therapy.
In cell therapy, damaged cells in the body are replaced or repaired using healthy cells, such as immune or stem cells. For instance, cell treatment known as hematopoietic stem cell transplantation (HSCT) has been utilised for many years to treat certain blood illnesses. New cell treatments have been developed in recent years, such as chimeric antigen receptor (CAR) T-cell therapy, which alters the immune system of a patient to target cancer cells.
- Gene Editing for Hemoglobinopathies
- CAR T-Cell Therapy for Hematologic Malignancies
- Gene Therapy for Inherited Bleeding Disorders
- Cell-Based Therapies for Thrombotic Disorders
Related Conference of Gene and Cell Therapies for Blood Disorders
Gene and Cell Therapies for Blood Disorders Conference Speakers
Recommended Sessions
- Anemia
- Biomarkers in Hematology
- Bleeding Disorders
- Clinical and Experimental Hematology
- Coagulopathies
- Gene and Cell Therapies for Blood Disorders
- Hematologic Malignancies
- Hematology and neurological disorders
- Hematology in COVID-19 patients
- Hematology in Pediatrics
- Hematology-oncology
- Hematopoietic Stem Cell Transplantation
- Hemostasis
- HIV/AIDS
- Immunohematology
- Immunotherapy for Blood Disorders
- Leukemia
- Myeloma
- Rare Blood Disorders
- Thalassemia
- Thrombosis and Hemostasis
Related Journals
Are you interested in
- Bleeding Disorders in Women - Blood Disorders 2024 (Ireland)
- Digital Health and Artificial Intelligence (AI) in Hematology - Blood Disorders 2024 (Ireland)
- Hematologic Gene Editing and Gene Therapies - Blood Disorders 2024 (Ireland)
- Hematology and Stem Cell Research - Blood Disorders 2024 (Ireland)
- Hematopoietic Stem Cell Transplantation - Blood Disorders 2024 (Ireland)
- Hemoglobinopathies and Sickle Cell Disease - Blood Disorders 2024 (Ireland)
- Hemophilia Management and Research - Blood Disorders 2024 (Ireland)
- Hemostasis and Thrombosis - Blood Disorders 2024 (Ireland)
- Immunotherapy and Hematology - Blood Disorders 2024 (Ireland)
- Leukemia and Lymphoma - Blood Disorders 2024 (Ireland)
- Medicine in Hematology - Blood Disorders 2024 (Ireland)
- Molecular Hematology - Blood Disorders 2024 (Ireland)
- Myelodysplastic Syndromes (MDS) and Bone Marrow Failure - Blood Disorders 2024 (Ireland)
- Next-Generation Diagnostics and Imaging - Blood Disorders 2024 (Ireland)
- Novel Therapies for Blood Cancers - Blood Disorders 2024 (Ireland)
- Pediatric Hematology - Blood Disorders 2024 (Ireland)
- Platelet Disorders - Blood Disorders 2024 (Ireland)
- Sickle Cell Disease (SCD) - Blood Disorders 2024 (Ireland)
- Thalassemia Management - Blood Disorders 2024 (Ireland)
- Transfusion Medicine and Blood Banking - Blood Disorders 2024 (Ireland)